The lack of relevant intratumoral heterogeneity of FGFR1 amplifications in our study suggests that anti-FGFR1 therapies may be effective in esophageal cancers harboring this alteration, and encourages future clinical trials in FGFR1 amplified ESCC. This evidence concerns the gene FGFR1 and esophageal squamous cell carcinoma.